Alvotech (ALVO) Share-based Compensation (2021 - 2026)
Alvotech's (ALVO) quarterly Share-based Compensation came in at $2.9 million in Q2 2026, up 38.44% on a YoY basis from $2.1 million in Q2 2025, and up 24.62% quarter-over-quarter from $2.3 million in Q1 2026.
Analysis
Alvotech (ALVO) Share-based Compensation (2021 - 2026) Analysis & Trends
Alvotech (ALVO) has reported Share-based Compensation for 6 consecutive years, with $2.9 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Share-based Compensation rose 38.44% year-over-year to $2.9 million; the trailing twelve-month figure through Jun 2026 stood at $9.2 million (up 60.43% YoY), and the FY2025 full-year result was $7.4 million, down 3.25% from the prior year.
- Share-based Compensation climbed to $2.9 million in Q2 2026 per ALVO's latest filing, from $2.3 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $20.6 million in Q4 2022 and bottomed at -$503000.0 in Q4 2025.
- Historically, Share-based Compensation has averaged $3.9 million across 5 years, with a median of $2.7 million in 2024.
- The sharpest annual moves came in 2022 and 2024: Share-based Compensation jumped 221.64% in 2022, then tumbled 109.0% in 2024.
- Over 5 years, Share-based Compensation stood at $20.6 million in 2022, then slumped by 86.25% to $2.8 million in 2023, then plunged by 109.0% to -$255000.0 in 2024, then tumbled by 97.25% to -$503000.0 in 2025, then surged by 680.72% to $2.9 million in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $2.9 million, $2.3 million, and -$503000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.84 Bn | 39.19 Bn | 2.15 Bn | 40.00 Mn |
| 2 | Viatris | 19.13 Bn | 18.24 Bn | 1.46 Bn | 30.40 Mn |
| 3 | Dr Reddys Laboratories | 9.91 Bn | 9.74 Bn | 396.53 Mn | 1.02 Mn |
| 4 | Amneal Pharmaceuticals | 5.51 Bn | 5.38 Bn | 334.51 Mn | 176,000.00 |
| 5 | Bausch Health Companies | 2.30 Bn | 464.50 Mn | 2.10 Bn | 54.00 Mn |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn | 2.92 Mn |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn | 11.41 Mn |
| 8 | Amphastar Pharmaceuticals | 1.00 Bn | 714.13 Mn | 93.47 Mn | 29.30 Mn |
| 9 | Fennec Pharmaceuticals | 402.10 Mn | 360.85 Mn | 17.15 Mn | 7.04 Mn |
| 10 | RedHill Biopharma | 178.35 Mn | 178.35 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.92 Mn |
| Mar 31, 2026 | 2.34 Mn |
| Dec 31, 2025 | -503,000.00 |
| Sep 30, 2025 | 4.46 Mn |
| Jun 30, 2025 | 2.11 Mn |
| Mar 31, 2025 | 1.31 Mn |
| Dec 31, 2024 | -255,000.00 |
| Sep 30, 2024 | 2.59 Mn |
| Jun 30, 2024 | 2.47 Mn |
| Mar 31, 2024 | 2.83 Mn |
| Dec 31, 2023 | 2.83 Mn |
| Jun 30, 2023 | 6.67 Mn |
| Dec 31, 2022 | 20.61 Mn |
| Jun 30, 2022 | 3.73 Mn |
| Dec 31, 2021 | 6.41 Mn |
| Sep 30, 2021 | -905,000.00 |